hVIVO acquires CRS units for €10 million
LONDON: hVIVO plc, a leading human challenge clinical trials organization, has acquired two clinical research units from German CRO CRS Clinical Research Services Management GmbH for €10 million. The Mannheim and Kiel units, known for cardiometabolic, immunology, and renal trials, add 120 beds to hVIVO’s capacity. The acquisition enhances hVIVO’s Phase I and II trials…